



# Vaccines and Biologics Work group

Rome HUG March 2006  
Steve Hess, Bruce Cohen

The global language of business

[www.gs1.org](http://www.gs1.org)



## Team Members - draft

<u>Name</u>	<u>Company</u>	<u>E-Mail Addresses</u>	<u>Confirmed interest</u>
<b>Belzak, Lisa</b>	CIDPC Phac	<a href="mailto:lisa_belzak@hc-sc.gc.ca"><u>lisa_belzak@hc-sc.gc.ca</u></a>	yes
<b>Cohen, Bruce</b>	GSK	<a href="mailto:bruce.x.cohen@GSK.com"><u>bruce.x.cohen@GSK.com</u></a>	Co-Lead
<b>Easterday, Lori</b>	Sanofi Pasteur Inc.	<a href="mailto:Lori.easterday@sanofipasteur.com"><u>Lori.easterday@sanofipasteur.com</u></a>	yes
<b>Eves, Peter</b>	GS1-UK	<a href="mailto:peter.eves@gs1uk.org"><u>peter.eves@gs1uk.org</u></a>	yes
<b>Hess, Steve</b>	Merck & Co., Inc.	<a href="mailto:stephen_hess@merck.com"><u>stephen_hess@merck.com</u></a>	Co-Lead
<b>Gilbert, Jayne</b>	Chiron	<a href="mailto:jayne_gilbert@chiron.com"><u>jayne_gilbert@chiron.com</u></a>	
<b>Gusev, Vlad</b>	Amgen	<a href="mailto:vgusev@amgen.com"><u>vgusev@amgen.com</u></a>	yes
<b>Mukaru, Alice</b>	GS1 UK	<a href="mailto:alice.mukaru@gs1uk.org"><u>alice.mukaru@gs1uk.org</u></a>	yes
<b>Pizzuto, Thomas</b>	Wyeth	<a href="mailto:pizzutt@wyeth.com"><u>pizzutt@wyeth.com</u></a>	
<b>Sanches, Jose-Javier</b>	GS1-Spain	<a href="mailto:jjsanchez@gs1es.org"><u>jjsanchez@gs1es.org</u></a>	yes
<b>Tomicki, Peter</b>	Baxter Healthcare	<a href="mailto:peter_tomicki@baxter.com"><u>peter_tomicki@baxter.com</u></a>	yes
<b>Torme, Carlos</b>	GS1-Spain	<a href="mailto:ctorme@gs1es.org"><u>ctorme@gs1es.org</u></a>	yes
<b>Wenninger, Bruce</b>	CDC	<a href="mailto:bgw2@cdc.gov"><u>bgw2@cdc.gov</u></a>	yes



## Objective:

Develop a global standard and increase adoption across the supply chain for vaccine and biological data aimed to improve patients safety and reduce medication errors.

## Scope:

One standard globally covering all biological and vaccine products and aspects of the supply chain



## Deliverables and timeline

Global guideline for vaccine and biological with agreed data elements and data carriers

- **Jan 2006 – Draft charter**
- **Feb 2006 – Form work team**
- **March 2006 – Report out in Roma**
- **2Q 2006 – Conduct Voice of the Customer**
- **June 2006 - Draft guideline**
- **3Q 2006 – Guideline approval and publish**
- **2007 – Establish adoption metrics**



## March 3'rd Kick off meeting

**Knowledge share on GS1 and the HUG**

**Mission and vision of HUG**

**Cascade sponsorship of the HUG**

**Initial concepts of**

**what is different with vaccines**

**what is different with biologicals**

**Enroll and engage team members**



## Are Vaccine and Biological different than Pharma products?

**How they are packaged?**

**How they are shipped and distributed?**

**How they are stored and inventoried?**

**How they are used throughout the supply chain?**

**How they impact the patient?**



## Packaging Differences

**Very small containers**

**Vials**

**Ampoules**

**Syringes (with and without diluents)**

**Unit dose pipettes**

**Bags**

**Peel off label requirements Vs Permanent pressure sensitive label**



# Distribution Differences

**Refrigerated conditions (2 – 8 C)**  
**Frozen on dry ice**



## How used by health care providers ?

**Dispensed at Dr office – US model**

**Picked up at pharmacy and carried to Dr office –  
EU model**

**Required to record lot # per patient – immunization  
record keeping**

**Wide range of cost – pennies/dose to \$ 1000/dose**

**Mass immunized – individualized medicines**


**Long term care facility**

**In home care**

**WHAT**

**HOW**

**Improve Patient  
Safety &  
Reduce  
Risks**





HUG  
Vaccine/Biological  
Workgroup

## Contact details

**Steve Hess Merck** [stephen\\_hess@merck.com](mailto:stephen_hess@merck.com)

**(908) 423 7674**

**Bruce Cohen GSK** [bruce.x.cohen@GSK.com](mailto:bruce.x.cohen@GSK.com)

**(919) 483-9375**

The global language of business

[www.gs1.org](http://www.gs1.org)